
Opinion|Videos|January 24, 2025
Key Strategies for Preventing CRS and ICANS
Panelists discuss key strategies for preventing cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) in patients receiving bispecific therapies for B-cell lymphomas.
Advertisement
Episodes in this series

Video content above is prompted by the following:
What are your key strategies for preventing CRS and ICANS in patients receiving bispecific therapies for B-cell lymphomas?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
'Tis the Season: SABCS 2025 to Highlight Latest Advances Across the Breast Cancer Continuum
2
Once-Monthly Maridebart Cafraglutide Shows Up to 16% Weight Loss
3
EPCORE FL-1: Adding Epcoritamab to R2 Delivers “New Benchmark” in Second-Line Follicular Lymphoma
4
Azacitidine/Venetoclax Combo Data Challenge Chemo in Fit Patients With AML
5












































